Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $685 thousand versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.